TTTY19: A Potential Drug Target for Testicular Cancer (G252952)

Target Name: TTTY19

NCBI ID: G252952

TTTY19

Other Name(s): Testis-specific transcript, Y-linked 19 | NCRNA00144 | testis-specific transcript, Y-linked 19

TTTY19: A Potential Drug Target for Testicular Cancer

TTTY19 is a protein that is expressed in testis and has been identified as a potential drug target or biomarker. The protein is named after its gene location on the Y chromosome and has been shown to play a role in the development and progression of testicular cancer.

TTTY19 and Testicular Cancer

Testicular cancer is a relatively rare form of cancer that affects young men. It is the most common type of cancer that affects the male genital system and is the second leading cause of cancer death in men. Despite advances in treatment, the survival rate for testicular cancer remains poor, with a five-year survival rate of only around 25%.

TTTY19 has been shown to be involved in the development and progression of testicular cancer. Studies have shown that high levels of TTTY19 are associated with a poor prognosis for testicular cancer and that inhibiting the activity of TTTY19 may be an effective way to treat this disease.

TTTY19 as a Drug Target

TTTY19 is a promising drug target because it is involved in the development and progression of testicular cancer. By inhibiting the activity of TTTY19, researchers may be able to slow down or even stop the growth of cancer cells. This could lead to a more effective treatment for testicular cancer.

TTTY19 has been shown to interact with a variety of molecules, including the protein PDGF-BB. PDGF-BB is a growth factor that has been shown to promote the growth and survival of many types of cancer cells. By inhibiting the activity of TTTY19, researchers may be able to reduce the effects of PDGF-BB on cancer cells.

TTTY19 as a Biomarker

TTTY19 has also been shown to be a potential biomarker for testicular cancer. By measuring the levels of TTTY19 in cancer cells, researchers may be able to monitor the effectiveness of different treatments and identify those that are most effective. This could lead to the development of more effective treatments for testicular cancer.

TTTY19 and Y-Chromosome

TTTY19 is located on the Y chromosome and has been shown to be involved in the development and progression of testicular cancer. This suggests that TTTY19 may be an important factor in the development of testicular cancer and could be a potential drug target or biomarker.

Conclusion

TTTY19 is a protein that has been shown to be involved in the development and progression of testicular cancer. By inhibiting the activity of TTTY19, researchers may be able to slow down or even stop the growth of cancer cells and lead to more effective treatments for this disease. TTTY19 is also a potential biomarker for testicular cancer and could be used to monitor the effectiveness of different treatments. Further research is needed to fully understand the role of TTTY19 in testicular cancer and to develop more effective treatments.

Protein Name: Testis-specific Transcript, Y-linked 19

The "TTTY19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTTY19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets